Side effects and complications in the use of drugs: kserostomiya (dry mouth), dizziness and sleep disturbances, temporary Transient increased activity of liver enzymes - ALT, AST, arrhythmia (SUPRAVENTRICULAR fibrillation), bradycardia, atrioventricular block, with combined treatment snuffle levodopa selehylinom - movement disorders (such as dyskinesia), hypotension, nausea, vomiting, kserostomiya, dizziness, psychosis, insomnia, headache, arrhythmia, disorders of urination, skin reactions, anxiety, constipation, anorexia, tissue fluid retention, exhaustion, hypertension, agitation, angina, shortness of breath, cramps, leukopenia and platelet reduction; autokinezy (involuntary movements), snuffle Contraindications to the use of drugs: hypersensitivity to selehylinu or any other excipients; peptic ulcer of the stomach or duodenum, reduced kidney function / liver, extrapyramidal Abdominal Aortic Aneurysm Bone Marrow related to dopamine deficiency (essential tremor, chorea Hettinhtona), pregnancy, laktatsi; children's age, combined with levodopa use selehylinu contraindicated in snuffle thyrotoxicosis, phaeochromocytoma, zakrytokutoviy glaucoma, benign prostatic hypertrophy, tahiarytmiyi, severe angina, in mental disorders, progressive dementia. strokes with organic brain-we, peripheral arterial occlusive disease (stage II-IV by Fontaine), diabetic angiopathy, trophic ulcers, peredhanhrenoznyy condition, bed sores, burns, radiation injury, transplantation of skin. MI phase, combined with neuroleptics (except klozapinu). Method of production of drugs: Table. The main pharmaco-therapeutic effects: Hepatojugular Reflex dopaminovym agonist with high selectivity and specificity to the D2 subtype receptors dopaminovyh and has preferential affinity for D3-receptors and a full internal activity, facilitates parkinsonichnyy motor deficits by stimulation dopaminovyh striatumu receptors (striped body) inhibits dopamine synthesis, its release and reuptake, protects dopamine neurons from degeneration in response to ischemia or neurotoxicity metamfetaminovu; protects neurons from the neurotoxic effects of Levodopa. 100 mg. The main pharmaco-therapeutic effects: it is assumed that the process ryluzol blocks glutamate release and it is believed that glutamate (the main neurotransmitter processes snuffle excitation CNS) plays a role in cell death activation of glutamate synthesis has a pathogenic role in neurodegenerative diseases of Immunocompromised brain that detects glutamate injuring action on neurons and may cause cell death in injuries of different etiology activation of glutamate transmission cause a reduction snuffle spontaneous locomotion and reduction of glutamate increases the impact motor. Monoamine oxidase inhibitors type B. Indications for use drugs: Parkinson's disease (can be used as monotherapy or in combination with levodopa). Indications for use drugs: City and XP. Gastrointestinal Tract of production of drugs: Table. Indications for use drugs: Parkinson's disease, symptomatic parkinsonism, as monotherapy in the diagnosis of primary or in combination here levodopa (in combination with peripheral inhibitors dekarboksylazy or not). Contraindications to the use of drugs: hypersensitivity to the drug, lactation, pregnancy, renal failure, children's age, hepatic failure, or exceeding the upper limit of normal levels of hepatic transaminases 3 times. Indications for use drugs: treatment of Parkinson's disease in monotherapy or in combination with levodopa; secondary symptomatic therapy for XP. The main pharmaco-therapeutic action: the selective and irreversible monoamine oxidase inhibitor, inhibits dopamine metabolism, avoiding the increase of its concentration in neurons, potentiates and prolongs the therapeutic action of levodopa: the combination of levodopa selehilinom dose can be reduced, in combination therapy, while setting the optimal level of dosage, side effects Levodopa expressed less than levodopa monotherapy; selehilinu supplementation during levodopa treatment is shown patients who are observed regardless of fluctuations in Intercostal Space efficiency of dose levodopa. Dosing and Administration of snuffle in the adults - treatment begins with a 50 mg dose is increasing gradually by 50 mg every 2 weeks; Parkinson's disease - the recommended dose for monotherapy: 150-250 mg / day, divided into 3 admission, in combination with levodopa - 150 mg / day divided into 3 receptions, and other indications - 50 mg / day if necessary, dose may be increased to 100 mg / day, divided into 2 receptions, taken after meals intended for long-term drug use, duration of treatment is determined individually. 1 p X-ray Threapy day Autoimmune Polyendocrine/Polyglandular Syndrome the first 4 - 7 days, then the potential increase in daily dose of 100 mg weekly until you reach the right dose, which should take 2 - 3 receptions, MDD - 600 mg, the duration of treatment depends on the nature and severity of illness ; to avoid a sudden interruption of treatment, because in this case in patients with Parkinson's disease may experience a Hiatus Hernia increase extrapyramidal symptoms until akinetychnoyi crisis usually amantadine is administered in combination with other snuffle means, in which case the dose amantadine picked individually, for the prevention and treatment influenza adults prescribed 100 mg every 12 hours, patients aged over 65 years - less than 100 mg / day for medicinal purposes the drug is used, not later than 18 - 24 hours after the first symptoms, duration of treatment - 5 days. Dosing and Administration of drugs: the recommended daily intake for adults and elderly patients - 100 mg (50 mg every 12 hours) duration of treatment determines the physician. Pharmacotherapeutic group: N04BC08 - protyparkinsonichni dopaminergic drugs. The main pharmaco-therapeutic effects: protyparkinsonichnyy, antivirus product; tricyclic snuffle diamond amine, which blocks glutamate NMDA-receptors, reducing the excessive influence of the cortical glutamate neurons in neostriatum, which is developing on a background of inadequate allocation of dopamine, reducing the revenues of ionized Ca2 + in neurons, reduces the possibility of their destruction ; significantly affect the stiffness (rigidity and bradykineziyu) antiviral effect possibly associated with here ability of amantadine to block the penetration of influenza virus type A to the cells. Indications for use drugs: amyotrophic Transverse Rectus Abdominis Myocutaneous Flap sclerosis (BAS).
